RSRichard Shikiar

Richard Shikiar

*This is an algorithmically generated author record based on publicly available information.

Richard Shikiar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 February 2007
      • Vol. 79  (2) , 157-62

    The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria.

    by Sheldon L Spector, Richard Shikiar, Gale Harding, Suzanne Meeves, Michael J Leahy

    The present study examined the impact of once-daily fexofenadine hydrochloride (HCl) 180 mg on health-related quality of life (HRQL) in subjects with chronic idiopathic urticaria (CIU). This was a multicenter, randomized, double-blind. parallel-group, placebo-controlled study. Subjects completed the Dermatology Life Quality Index (DLQI) and the Work Productivity and Activity Impairment (WPAI) questionnaire at baseline and at weeks 2 and 4. The primary HRQL end point was mean change from baseline to week 4 in total DLQI score. Subjects in the fexofenadine HCl treatment group (n = 163) experienced significantly greater improvements in mean total DLQI score (P = .0219) and in the individual domains of symptoms and feelings (P = .0119) and personal relationships (P = .0091) compared with those in the placebo group (n = 91). Subjects who received fexofenadine HCl experienced less work productivity impairment, overall work impairment, and activity impairment than those who received placebo. The results indicated that once-daily fexofenadine HCl 180 mg improved the HRQL of subjects with CIU, as assessed by change in total DLQI score.


  • Development and Validation of the Gastroesophageal Reflux Disease Treatment Satisfaction Questionnaire

    by Richard Shikiar, Emuella Flood, Reshmi Siddique, Jamie Howell, Sheri L. Dodd

    There is growing recognition of the importance of assessing patient perceptions of treatment, especially patient satisfaction. The Gastroesophageal Reflux Disease (GERD) Treatment Satisfaction Questionnaire (GTSQ) was developed to assess satisfaction with GERD medication. A web-based survey, which included the GTSQ and the GERD Symptom Assessment Scale (GSAS), was administered in September 2003 to 2511 subjects taking prescription GERD medication, identified as H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs). Results showed excellent reliability of the GTSQ subscales (from 0.82–0.95) and validity with respect to two GSAS subscales. Rabeprazole (Aciphex) subjects taking 1 pill per day were statistically more satisfied than those taking 2 pills per day for all subscales except “Daytime Relief” and “Quick and Long-Lasting.” Those who stayed on rabeprazole therapy longer showed statistically significant greater satisfaction on the “Daytime Relief” and “Health-Related Quality of Life” scales. The GTSQ has high reliability and can be used to assess aspects of satisfaction with GERD medication.


  • Open Access

    Minimal Important Difference (MID) of the Dermatology Life Quality Index (DLQI): Results from patients with chronic idiopathic urticaria

    by Richard Shikiar, Gale Harding, Michael Leahy, Richard D Lennox

    Background: The Dermatology Quality Life Index (DLQI) has seen widespread use as a health-related quality of life measure for a variety of dermatological diseases. The purpose of this study was to estimate the minimal important difference (MID) on the DLQI for patients with chronic idiopathic urticaria (CIU). Methods: Data from 2 Phase III clinical trials of patients (N = 476 for Study A; N = 468 for Study B) with CIU were analyzed separately to estimate the MID for the DLQI for these populations. Both distributional based and anchor based approaches were used for deriving estimates. The anchor based approach relied upon patient self assessments of pruritus severity; the distributional based approaches relied upon estimating the standard error of measurement, as well as one-half the standard deviation of the DLQI from each study. Results: The distributional approaches resulted in estimates of MID ranging from 2.24 to 3.10 for the two studies. The anchor based approach resulted in estimates of 3.21 and 2.97 for the two studies. Conclusion: An MID for the DLQI in the range of 2.24 to 3.10 is recommended in interpreting results for patients with CIU.


  • Open Access

    Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials

    by Richard Shikiar, Brian W Bresnahan, Stephen P Stone, Christine Thompson, John Koo, Dennis A Revicki

    Two Phase III randomized controlled clinical trials were conducted to assess the efficacy, safety, and tolerability of weekly subcutaneous administration of efalizumab for the treatment of psoriasis. Patient reported measures of psoriasis-related functionality and health-related quality of life and of psoriasis-related symptom assessments were included as part of the trials.